Trial Information
Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)
Inclusion Criteria:
- Histologically confirmed diagnosis of Hodgkin disease
- Clinical stage IIB, III, IV
- No prior treatment for Hodgkin disease or other malignancy
- Age 18-65 year
- Good cardiac, pulmunar, renal and hepatic function
- Performance status 0-3 (Karnofsky 100- 40)
- Written Informed Consent
Exclusion Criteria:
- HIV positivity
- Large cell, anaplastic, CD30+ lymphoma
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens
Principal Investigator
Paolo Gobbi, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
GISL
Authority:
Italy: Ethics Committee
Study ID:
HD2000
NCT ID:
NCT00443677
Start Date:
April 2000
Completion Date:
June 2007
Related Keywords:
- Advanced Hodgkin Disease
- Hodgkin Disease